Navigation Links
Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
Date:5/3/2012

llion.  Net cash used in operating activities was $23.3 million for the first quarter, while purchases of capital equipment for the same period totaled $1.8 million, funded primarily through utilization of the Company's credit facility.  As of March 31, 2012, the Company had borrowed $17.0 million under the credit facility.

Operational UpdatesThe Company recently reported that more than 12,700 total tests, including in excess of 4,900 MaterniT21 PLUS laboratory-developed tests (LDT) offered by Sequenom CMM, were accessioned during the first quarter of 2012, a 140% increase over the same period in 2011.
At the close of the first quarter of 2012, the number of MaterniT21 PLUS samples accessioned on an annualized basis equated to approximately 30,000 tests. As of the last week in April, the 52-week run rate had increased to more than 45,000 tests.  

"The first quarter of 2012 has been an active and productive one for Sequenom and Sequenom CMM, as we have received and responded to the strong interest in Sequenom CMM's testing services, particularly with regard to Sequenom CMM's MaterniT21 PLUS LDT," said Harry Hixson, Jr., Ph.D., Chairman and CEO of Sequenom.  "It is our goal to build on this positive momentum as the year progresses.  We will continue to expand our reach to meet growing demand and deliver on our objective of providing high quality testing services offered by Sequenom CMM to physician customers nationwide."

Due to the successful growth in adoption year-to-date, the Company also increased its internal goal to 40,000 MaterniT21 PLUS LDTs billed for the calendar year 2012, up from the original goal of billing 25,000 tests for the year.

In response to the growing commercial interest and demand for its testing services, Sequenom CMM expanded its prenatal sales force during the first quarter, adding 23 new sales representatives, and three additional retinal sales representatives,
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sequenom, Inc. Announces Date of Third Quarter 2011 Financial Results and Conference Call
2. Neuland Labs Reports Financial Results For Fiscal Year 2012
3. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
4. GP Strategies Reports Strong First Quarter 2012 EPS of $0.23
5. Cardinal Health Reports Third-Quarter Results
6. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Neurocrine Biosciences Reports First Quarter 2012 Results
9. CVS Caremark Reports Record First Quarter Results
10. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
11. Thoratec Reports First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical ... today announced the filing of a registration statement on ... (SEC) relating to a proposed initial public offering of ... offered and the price range for the offering have ... common stock under the symbol "CTMX" on the NASDAQ ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Originally discovered by Welfide (Mitsubishi ... Industries, Ltd) as an inflammatory drug, pranoprofen was ... Co., Ltd under the trade name of pranopulin ...
(Date:8/28/2015)... -- Research and Markets ( ... "12th Annual Report and Survey of Biopharmaceutical ... offering. The 2015 12th Annual Report ... is the most recent study of biotherapeutic developers ... capacity and production. The report contains the industry,s ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... 2011 Covance Inc. (NYSE: CVD ) today ... Healthcare Conference on Thursday, February 24, 2011 at 10:00 a.m. ... at www.covance.com .  In order to register and download ... Covance, with headquarters in Princeton, New Jersey, is one ...
... IRVINE, Calif., Feb. 22, 2011 Endologix, Inc. (Nasdaq: ... disorders, today announced financial results for the three and twelve ... Endologix President and Chief Executive Officer, said, "We made tremendous ... quarter of 2010.  Revenue grew by 41% over the corresponding ...
Cached Medicine Technology:Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 2Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 3Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 4Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 5Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 6Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 7Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 8Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 9Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 10
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... the student experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 ... This is the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Understanding the FDA’s Position and Best Practices for Compliance, **Presented by FDAnews ... This workshop, chaired by internationally renowned expert Fubin Wu, has been specifically ...
(Date:8/28/2015)... Manistee, Michigan (PRWEB) , ... August 28, 2015 ... ... or alcohol abuse, or those who might personally be struggling with chemical dependency, ... blog post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction ...
(Date:8/28/2015)... ... 28, 2015 , ... Drugs and alcohol abuse by employees ... new approach on solutions in his new book ":Unraveling The Psychological Mystery of ... together for meaningful group meetings. "This would educate the employees on not ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... Aug. 3 Blue Cross and Blue Shield of Georgia ... administration of the H1N1 (swine flu) vaccine when it becomes ... be covered for members whose benefit plans provide coverage for ... coverage of seasonal flu vaccine administration for those whose health ...
... A new class of antibody drugs may provide a powerful ... but specialists need to be alert for the possibility of ... Journal of AAPOS (American Association for Pediatric Ophthalmology ... of Santa Barbara, Calif., discusses issues related to the use ...
... of synthetic biology will, in the medium term, open up ... with engineering principles. This will facilitate the development, not only ... new materials. Early-stage dialogue with the public on the natural ... success and acceptance of this new technology. With a joint ...
... 3 Medial Saude S/A,(BOVESPA: MEDI3) (MEDIAL SAUDE) announces the following webcast: , , ... When: Friday, August 14, 2009 at 12:00 PM ET, ... Live over the Internet -- Simply log on to the web at the, ... Conference call dial-in phone numbers:, Toll-free from the US: ...
... , SILVER SPRING, Md., Aug. 3 Four ... session of ongoing couples therapy can greatly increase chances for ... The largest clinical trial with couples to date, it shows ... feedback technique were 46.2 percent less than that of couples ...
... INCLINE VILLAGE, Nev., Aug. 3 PDL BioPharma, Inc. (PDL) ... E. ("Barry") Selick, Ph.D., to the Company,s Board of Directors. , ... and his extensive knowledge of PDL,s humanization technology will allow him ... seek to maximize the value of our antibody humanization patents and ...
Cached Medicine News:Health News:BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 2Health News:Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases 2Health News:Synthetic biology -- opportunities and risks 2Health News:Synthetic biology -- opportunities and risks 3Health News:Therapy Technique Cuts Divorce/Separation Rate By Nearly 50 Percent 2Health News:PDL BioPharma Elects Barry Selick to Its Board of Directors 2
... capture the patient`s exhaled heat and moisture ... Small and compact, they are specially treated ... on the tidal volume requirements, select either ... adult HCH is ideal for patient tidal ...
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
HME only...
Medicine Products: